TJ242B - A method of treatment an ovarian estrogen dependent condition - Google Patents

A method of treatment an ovarian estrogen dependent condition

Info

Publication number
TJ242B
TJ242B TJ96000402A TJ96000402A TJ242B TJ 242 B TJ242 B TJ 242B TJ 96000402 A TJ96000402 A TJ 96000402A TJ 96000402 A TJ96000402 A TJ 96000402A TJ 242 B TJ242 B TJ 242B
Authority
TJ
Tajikistan
Prior art keywords
dependent condition
treatment
estrogen dependent
ovarian estrogen
administration
Prior art date
Application number
TJ96000402A
Inventor
Gary D Hodger
Robert F Willaims
Daniel Grow
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of TJ242B publication Critical patent/TJ242B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A method of treating an ovarian estrogen dependent condition such as endometriosis, uterine leiomyomata, PMS or DUB involving the administration of gonadotropin releasing hormone analog and the administration of antiprogestin, which will provide a therapeutic method for long term treatment without rapid loss of bone density, as occurs using GnRH analogs alone.
TJ96000402A 1994-02-04 1995-02-02 A method of treatment an ovarian estrogen dependent condition TJ242B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/191,631 US5681817A (en) 1994-02-04 1994-02-04 Treatment of ovarian estrogen dependent conditions
PCT/US1995/001479 WO1995020972A1 (en) 1994-02-04 1995-02-02 Treatment of ovarian estrogen dependent conditions

Publications (1)

Publication Number Publication Date
TJ242B true TJ242B (en) 1999-11-24

Family

ID=22706258

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000402A TJ242B (en) 1994-02-04 1995-02-02 A method of treatment an ovarian estrogen dependent condition

Country Status (29)

Country Link
US (1) US5681817A (en)
EP (1) EP0785792B1 (en)
JP (1) JP3130048B2 (en)
KR (1) KR970700507A (en)
CN (1) CN1144486A (en)
AP (1) AP724A (en)
AT (1) ATE179610T1 (en)
AU (1) AU689229B2 (en)
BG (1) BG62238B1 (en)
BR (1) BR9506606A (en)
CA (1) CA2182183C (en)
CZ (1) CZ291709B6 (en)
DE (1) DE69509544T2 (en)
DK (1) DK0785792T3 (en)
ES (1) ES2132645T3 (en)
FI (1) FI963036L (en)
GR (1) GR3030164T3 (en)
HU (1) HUT74622A (en)
LT (1) LT4182B (en)
LV (1) LV11782B (en)
MD (1) MD1432C2 (en)
NZ (1) NZ281441A (en)
OA (1) OA10777A (en)
PL (1) PL178273B1 (en)
RO (1) RO117420B1 (en)
RU (1) RU2110274C1 (en)
SK (1) SK96296A3 (en)
TJ (1) TJ242B (en)
WO (1) WO1995020972A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL114655A (en) * 1994-07-22 2005-08-31 Hampton Roads Medical College USE OF GnRH ANTAGONIST IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF A GONADAL-STEROID DEPENDENT CONDITION IN A MAMMAL
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
JP4418102B2 (en) 1997-10-17 2010-02-17 持田製薬株式会社 Treatment for uterine fibroids containing dienogest as an active ingredient
US6703367B1 (en) 1999-04-27 2004-03-09 Praecis Pharmaceuticals Inc. Methods for treating hot flashes and gynaecomastia
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
CA2382580C (en) * 1999-08-31 2009-05-19 Jenapharm Gmbh & Co. Kg Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
WO2002036144A1 (en) * 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
US6960337B2 (en) * 2002-08-02 2005-11-01 Balance Pharmaceuticals, Inc. Methods and compositions for treating benign gynecological disorders
US7029657B2 (en) * 2002-08-02 2006-04-18 Balance Pharmaceuticals, Inc. Nasal spray steroid formulation and method
US6958142B2 (en) * 2002-08-02 2005-10-25 Balance Pharmaceuticals, Inc. Nasal spray formulation and method
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment
EP2316441A1 (en) * 2005-02-17 2011-05-04 Hadasit Medical Research Services And Development Bisphosphonates for treating endometriosis
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
US7862552B2 (en) 2005-05-09 2011-01-04 Boston Scientific Scimed, Inc. Medical devices for treating urological and uterine conditions
TWI455716B (en) * 2006-10-24 2014-10-11 Repros Therapeutics Inc Use of a se1ective progesterone receptor modulator for the manufacture of a medicament for treating an estrogen dependent condition
HUE036870T2 (en) * 2006-10-24 2018-08-28 Repros Therapeutics Inc Compositions and methods for suppressing endometrial proliferation
WO2008144143A1 (en) * 2007-05-14 2008-11-27 Drugtech Corporation Endometriosis treatment
DK2197415T3 (en) * 2007-09-20 2014-05-26 Lapidot Medical Imp And Marketing Ltd Compositions and agents for treating uterine leiomyomas, leiomyoma, myoma, uterine fibroid, endometriosis, adenomyosis and related mifepristone disorders
RU2359684C1 (en) * 2008-01-23 2009-06-27 Закрытое акционерное общество "СКАЙ ЛТД" Way of endometriosis treatment
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
DE3347126A1 (en) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11SS-ARYL-ESTRADIENE, THEIR PRODUCTION AND THE PHARMACEUTICAL PREPARATIONS CONTAINING THEM
ES2054784T3 (en) 1987-08-08 1994-08-16 Akzo Nv A METHOD FOR THE MANUFACTURE OF AN IMPLANT.
DE3744054A1 (en) 1987-12-21 1989-06-29 Schering Ag USE OF ANTIGESTAGES FOR THE PRODUCTION OF MEDICINAL PRODUCTS
DE3921059A1 (en) 1989-06-23 1991-01-10 Schering Ag 11 (BETA) -ARYL-4-ESTRENE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT
WO1991014704A2 (en) 1990-03-16 1991-10-03 Applied Research Systems Ars Holding N.V. Treatment of polycystic ovarian disease
US6827050B2 (en) 2001-12-21 2004-12-07 Caterpillar Inc Fluid control valve actuating system
US7283632B2 (en) 2003-09-09 2007-10-16 The Boeing Company Unauthorized access embedded software protection system

Also Published As

Publication number Publication date
JP3130048B2 (en) 2001-01-31
MD1432B2 (en) 2000-03-31
BG100766A (en) 1997-06-30
DK0785792T3 (en) 1999-10-18
EP0785792A4 (en) 1997-07-30
PL315792A1 (en) 1996-12-09
OA10777A (en) 2002-12-23
GR3030164T3 (en) 1999-08-31
EP0785792A1 (en) 1997-07-30
CA2182183A1 (en) 1995-08-10
CN1144486A (en) 1997-03-05
CZ291709B6 (en) 2003-05-14
LT96133A (en) 1997-01-27
JPH09508418A (en) 1997-08-26
AP9600840A0 (en) 1996-07-31
RU2110274C1 (en) 1998-05-10
BG62238B1 (en) 1999-06-30
DE69509544D1 (en) 1999-06-10
SK96296A3 (en) 1997-07-09
US5681817A (en) 1997-10-28
MD1432C2 (en) 2000-09-30
CZ210396A3 (en) 1997-05-14
LV11782A (en) 1997-06-20
ES2132645T3 (en) 1999-08-16
AP724A (en) 1999-01-18
DE69509544T2 (en) 1999-09-02
RO117420B1 (en) 2002-03-29
AU689229B2 (en) 1998-03-26
CA2182183C (en) 2003-09-16
FI963036A0 (en) 1996-08-01
FI963036A7 (en) 1996-08-01
WO1995020972A1 (en) 1995-08-10
KR970700507A (en) 1997-02-12
HU9601969D0 (en) 1996-09-30
PL178273B1 (en) 2000-03-31
FI963036L (en) 1996-08-01
LT4182B (en) 1997-06-25
BR9506606A (en) 1997-09-09
LV11782B (en) 1997-12-20
HUT74622A (en) 1997-01-28
ATE179610T1 (en) 1999-05-15
EP0785792B1 (en) 1999-05-06
NZ281441A (en) 1999-09-29
AU1838695A (en) 1995-08-21

Similar Documents

Publication Publication Date Title
TJ242B (en) A method of treatment an ovarian estrogen dependent condition
IL124459A0 (en) Antagonists of gonadotropin releasing hormone
MX9804850A (en) Antagonists of gonadotropin releasing hormone.
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
TW366342B (en) The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss
PL327182A1 (en) Method of preventing conception among female mammals through combined application of gestagen and oestrogen and combination of active agent therefor
GR3031716T3 (en) Immunogens against gonadotropin releasing hormone
ZA941786B (en) Sulfonate and carbamate derivatives of 3-aroylbenzo(b)thiophenes
FI970260L (en) Progesterone antagonist and progestogen for the treatment of endometriosis and leiomyomata uteri
NZ323456A (en) Pharmaceutical composition of an estrogen agonist/antagonist and a prostaglandin or a prostaglandin agonist/antagonist; useful for combination therapy for osteoporosis
DE69710896D1 (en) Progestogen-anti-progestogen therapien
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
NO20005145L (en) Procedure for treating fertility problems
CA2137595A1 (en) Treating hormone-dependent conditions
NO985573L (en) Growth Hormone Component and Bone Anti-Absorbent in Cyclic (Coherence) Treatment of Osteoporosis
WO2000021511A3 (en) Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis
UA41351C2 (en) Contraception method and tablets for contraception
CA2248841A1 (en) Sequential oestrogen/progesterone antagonist combination for hormone replacement therapy
UA29349A (en) Method for treating anovulatory infertility
GB2369574A (en) Initiation of oestrus
UA29965A (en) Method for modeling acute stomach ulcer
GEP19991860B (en) Method for Treatment of Ovarian Estrogen Dependent Conditions
MX9701531A (en) Combination therapy to treat osteoporosis-polyphosphonates or progestins and estrogen agonists.
MX9702207A (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy.